WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H406596
CAS#: 1168092-22-5
Description: G-479 is an potent MEK inhibitor. Structurally, G-479 is an analogue of GDC-0623 (or so-call Me-Too drug). G-479 with polarity distributed throughout the molecule was shown improved bioactivity over GDC-0623 in many aspects.
Hodoodo Cat#: H406596
Name: G-479
CAS#: 1168092-22-5
Chemical Formula: C16H15FIN5O4
Exact Mass: 487.02
Molecular Weight: 487.220
Elemental Analysis: C, 39.44; H, 3.10; F, 3.90; I, 26.05; N, 14.37; O, 13.14
Synonym: G479; G-479; G 479.
IUPAC/Chemical Name: (R)-N-(2,3-dihydroxypropoxy)-5-((2-fluoro-4-iodophenyl)amino)imidazo[1,5-a]pyrazine-6-carboxamide
InChi Key: OKOKEHVACWMOFN-LLVKDONJSA-N
InChi Code: InChI=1S/C16H15FIN5O4/c17-12-3-9(18)1-2-13(12)21-15-14(16(26)22-27-7-11(25)6-24)20-5-10-4-19-8-23(10)15/h1-5,8,11,21,24-25H,6-7H2,(H,22,26)/t11-/m1/s1
SMILES Code: O=C(C1=C(NC2=CC=C(I)C=C2F)N3C(C=N1)=CN=C3)NOC[C@H](O)CO
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: G479 is Me-Too version of GDC-0623. Their structures are shown below (side-by-side comparison) G479 is Me-Too version of GDC-0623. Their structures are shown below (side-by-side comparison)
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 487.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Robarge KD, Lee W, Eigenbrot C, Ultsch M, Wiesmann C, Heald R, Price S, Hewitt J, Jackson P, Savy P, Burton B, Choo EF, Pang J, Boggs J, Yang A, Yang X, Baumgardner M. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479. Bioorg Med Chem Lett. 2014 Oct 1;24(19):4714-23. doi: 10.1016/j.bmcl.2014.08.008. Epub 2014 Aug 15. PubMed PMID: 25193232.
